NCT04290793 2026-01-07
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2/3 Active not recruiting
Clinical Trials
11 trialsNCT01779206 2025-04-08
ADAPT
West German Study Group
Phase 2/3 Completed
NCT02641847 2024-01-25
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
Fudan University
Phase 2/3 Active not recruiting
NCT01057069 2022-10-12
neo-TN
The Netherlands Cancer Institute
Phase 2/3 Active not recruiting
NCT04576143 2021-08-12
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Recruiting
NCT00448266 2021-01-22
Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT01907529 2019-08-09
TENDENCY
Hebei Medical University Fourth Hospital
Phase 2/3 Unknown
NCT03373708 2017-12-18
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Shandong Cancer Hospital and Institute
Phase 2/3 Unknown
NCT03349177 2017-11-21
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2/3 Unknown
NCT01204437 2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3 Completed
NCT00525642 2007-09-06
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Fudan University
Phase 2/3 Unknown